AU8112594A - 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists - Google Patents

4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists

Info

Publication number
AU8112594A
AU8112594A AU81125/94A AU8112594A AU8112594A AU 8112594 A AU8112594 A AU 8112594A AU 81125/94 A AU81125/94 A AU 81125/94A AU 8112594 A AU8112594 A AU 8112594A AU 8112594 A AU8112594 A AU 8112594A
Authority
AU
Australia
Prior art keywords
methylimidazo
pyridinylmethyl
antagonists
carboxylic acid
acid derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU81125/94A
Inventor
Stephen Arthur Bowles
Andrew Miller
Mark Whittaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
British Biotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharmaceuticals Ltd filed Critical British Biotech Pharmaceuticals Ltd
Publication of AU8112594A publication Critical patent/AU8112594A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU81125/94A 1993-11-10 1994-11-09 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists Abandoned AU8112594A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9323162 1993-11-10
GB939323162A GB9323162D0 (en) 1993-11-10 1993-11-10 4-(1h-2-methylimidazo(4,5-c)pyridinylmethyl)phenylsulphonamid e derivatives as antagonists of paf
PCT/GB1994/002460 WO1995013064A1 (en) 1993-11-10 1994-11-09 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists

Publications (1)

Publication Number Publication Date
AU8112594A true AU8112594A (en) 1995-05-29

Family

ID=10744942

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81125/94A Abandoned AU8112594A (en) 1993-11-10 1994-11-09 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists

Country Status (6)

Country Link
EP (1) EP0727995A1 (en)
JP (1) JPH09505040A (en)
AU (1) AU8112594A (en)
CA (1) CA2176124A1 (en)
GB (1) GB9323162D0 (en)
WO (1) WO1995013064A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508748D0 (en) * 1995-04-28 1995-06-14 British Biotech Pharm Benzimidazole derivatives
ES2284180T3 (en) 1996-01-23 2007-11-01 SHIONOGI & CO., LTD. DERIVATIVES OF SULFONATED AMINO ACIDS AND INHIBITORS OF METALOPROTEINASES CONTAINING THE SAME.
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
IL128079A0 (en) * 1996-07-22 1999-11-30 Monsanto Co Thiol sulfone metalloprotease inhibitors
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
JP2005537228A (en) 2002-04-25 2005-12-08 ファルマシア・コーポレーション Piperidinyl- and piperazinyl-sulfonylmethylhydroxamic acids and their use as protease inhibitors
EP2358202B1 (en) * 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98673B (en) * 1990-08-15 1999-01-29 British Bio Technology METHOD FOR PREPARING COMPOUNDS THAT ARE ANTAGONISTS OF THE ACTIVATION FACTOR OF PLATELETS FOR EXAMPLE DERIVATIVES OF BENZIMIDAZOLE AND THEIR INTERMEDIARIES

Also Published As

Publication number Publication date
JPH09505040A (en) 1997-05-20
CA2176124A1 (en) 1995-05-18
GB9323162D0 (en) 1994-01-05
WO1995013064A1 (en) 1995-05-18
EP0727995A1 (en) 1996-08-28

Similar Documents

Publication Publication Date Title
FI934460A (en) Carboxylic acid derivatives
AU1108395A (en) Heterocyclic biphenylylamides useful as 5ht1d antagonists
GR3015622T3 (en) Substituted pipecolinic acid derivatives as HIV protease inhibitors.
AU7334394A (en) Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
AU5256193A (en) Quinolone- and naphthyridonecarboxylic acid derivatives
AU1246995A (en) Alpha-quaternary-alpha-amino acids for use as cns agents
AU1600392A (en) Substituted carboxylic acid derivatives
AU7930394A (en) Pyrimidinyl-glutamic acid derivatives
AU646596B2 (en) Substituted imidazolyl-propenoic acid derivatives
AU2759892A (en) N-aryl-n1-azabicyclo-ureas as 5-ht3 antagonists
FI972684A0 (en) Piperidinetic acid derivatives which can be used as fibrinogen antagonists
AU8112594A (en) 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists
AU5455194A (en) Substituted phthalazinones as nerotensin antagonists
AU2219192A (en) Bicyclic carboxylic acid derivatives
AU673895B2 (en) Heterocyclic iminobismethylenebisphosphonic acid derivatives
AU4451797A (en) 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds
FI960634A (en) New quinolone carboxylic acid derivatives
AU6519994A (en) Quinazolinones substituted with phenoxyphenylacetic acid derivatives
HU9601167D0 (en) 5-arylisoxazol-4-yl-substituted 2-amino carboxylic acid compounds
GB2298138B (en) 4-(1h-2-methylimidazo 4,5-c pyridinylmethyl)phenyl sulphonamide carboxylic acid derivatives as antagonists
AU6337694A (en) Acid microemulsion composition
HRP940833A2 (en) 1-(2-fluorocyclopropyl)-quinoline- and naphthyridone carboxylic acid derivatives
AU7379794A (en) Aza-5,5-fused heterocyclic acids as leukotriene antagonists
AU6142494A (en) Oxadiazole carboxylic acid derivatives
GR3033237T3 (en) Quinoline derivatives as leukoriene antagonists.